Vertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment model for gene-based sickle cell anemia treatments, the agency announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results